Orrin Devinsky

Dr. Orrin Devinsky

orcid

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1995 in Brain
Verified
Journal Article
Closed access
PDF file
ODOrrin Devinsky
Orrin Devinsky
MMMartha J. Morrell
Martha J. Morrell
BVBrent A. Vogt
Brent A. Vogt
Assessments of anterior cingulate cortex in experimental animals and humans have led to unifying theories of its structural organization and contributions to mammalian behaviour. The anterior cingulate cortex forms a large region around the rostrum of the corpus callosum that is termed the anterior executive region. This region has numerous projections into motor systems, however, since these projections originate from different parts of anterior cingulate cortex and because functional studies have shown that it does not have a uniform contribution to brain functions, the anterior executive region is further subdivided into ‘affect’ and ‘cognition’ components. The affect division includes areas 25, 33 and rostral area 24, and has extensive connections with the amygdala and periaqueductal grey, and parts of it project to autonomic brainstem motor nuclei. In addition to regulating autonomic and endocrine functions, it is involved in conditioned emotional learning, vocalizations associated with expressing internal states, assessments of motivational content and assigning emotional valence to internal and external stimuli, and maternal—infant interactions. The cognition division includes caudal areas 24' and 32', the cingulate motor areas in the cingulate sulcus and nociceptive cortex. The cingulate motor areas project to the spinal cord and red nucleus and have premotor functions, while the nociceptive area is engaged in both response selection and cognitively demanding information processing. The cingulate epilepsy syndrome provides important support of experimental animal and human functional imaging studies for the role of anterior cingulate cortex in movement, affect and social behaviours. Excessive cingulate activity in cases with seizures confirmed in anterior cingulate cortex with subdural electrode recordings, can impair consciousness, alter affective state and expression, and influence skeletomotor and autonomic activity. Interictally, patients with anterior cingulate cortex epilepsy often display psychopathic or sociopathic behaviours. In other clinical examples of elevated anterior cingulate cortex activity it may contribute to tics, obsessive—compulsive behaviours, and aberrent social behaviour. Conversely, reduced cingulate activity following infarcts or surgery can contribute to behavioural disorders including akinetic mutism, diminished self-awareness and depression, motor neglect and impaired motor initiation, reduced responses to pain, and aberrent social behaviour. The role of anterior cingulate cortex in pain responsiveness is suggested by cingulumotomy results and functional imaging studies during noxious somatic stimulation. The affect division of anterior cingulate cortex modulates autonomic activity and internal emotional responses, while the cognition division is engaged in response selection associated with skeletomotor activity and responses to noxious stimuli. Overall, anterior cingulate cortex appears to play a crucial role in initiation, motivation, and goal-directed behaviours. The anterior cingulate cortex is part of a larger matrix of structures that are engaged in similar functions. These structures form the rostral limbic system and include the amygdala, periaqueductal grey, ventral striatum, orbitofrontal and anterior insular cortices. The system formed by these interconnected areas assesses the motivational content of internal and external stimuli and regulates context-dependent behaviours.

3 May 2018 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
ODOrrin Devinsky
Orrin Devinsky
AVAnnamaria Vezzani
Annamaria Vezzani
TOTerence J. O'Brien
Terence J. O'Brien
NJNathalie Jette
Nathalie Jette
ISIngrid E. Scheffer
Ingrid E. Scheffer
PPPiero Perucca
Piero Perucca

22 December 2014 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
DKDion Khodagholy
Dion Khodagholy
JGJennifer N Gelinas
Jennifer N Gelinas
TTThomas Thesen
Thomas Thesen
WDWerner Doyle
Werner Doyle
ODOrrin Devinsky
Orrin Devinsky
GBGyörgy Buzsáki
György Buzsáki
In this technical report, Khodagholy and colleagues find that NeuroGrid, a planar, scalable and highly conformable electrode array, allows recordings of local-field potentials and stable single-unit activity from the surface of the rat cortex or hippocampus. The authors also validate NeuroGrid across species by showing that that it can capture LFP-modulated spiking activity intraoperatively in surgical patients, thus demonstrating its utility as tool for fundamental research on the human brain and in the clinic. Recording from neural networks at the resolution of action potentials is critical for understanding how information is processed in the brain. Here, we address this challenge by developing an organic material–based, ultraconformable, biocompatible and scalable neural interface array (the ‘NeuroGrid’) that can record both local field potentials(LFPs) and action potentials from superficial cortical neurons without penetrating the brain surface. Spikes with features of interneurons and pyramidal cells were simultaneously acquired by multiple neighboring electrodes of the NeuroGrid, allowing for the isolation of putative single neurons in rats. Spiking activity demonstrated consistent phase modulation by ongoing brain oscillations and was stable in recordings exceeding 1 week's duration. We also recorded LFP-modulated spiking activity intraoperatively in patients undergoing epilepsy surgery. The NeuroGrid constitutes an effective method for large-scale, stable recording of neuronal spikes in concert with local population synaptic activity, enhancing comprehension of neural processes across spatiotemporal scales and potentially facilitating diagnosis and therapy for brain disorders.

17 May 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
ODOrrin Devinsky
Orrin Devinsky
APAnup D. Patel
Anup D. Patel
JCJ. Helen Cross
J. Helen Cross
VVVicente Villanueva
Vicente Villanueva
EWElaine C. Wirrell
Elaine C. Wirrell
SZSameer M. Zuberi
Sameer M. Zuberi
Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox–Gastaut syndrome, a severe developmental epileptic encephalopathy.

22 May 2014 in Epilepsia
Verified
Journal Article
Open access
PDF file
ODOrrin Devinsky
Orrin Devinsky
MCMaria Roberta Cilio
Maria Roberta Cilio
HCHelen Cross
Helen Cross
JFJavier Fernandez‐Ruiz
Javier Fernandez‐Ruiz
JFJacqueline French
Jacqueline French
DFDaniel Friedman
Daniel Friedman
Summary: To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. Δ9‐Tetrahydrocannabinol (Δ9‐THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and Δ9‐THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of Δ9‐THC limit tolerability. CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G‐protein‐coupled receptor GPR55; the transient receptor potential of vanilloid type‐1 channel; the 5‐HT1a receptor; and the α3 and α1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high‐ratio CBD:Δ9‐THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy. However, we lack data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder. Initial dose‐tolerability and double‐blind randomized, controlled studies focusing on target intractable epilepsy populations such as patients with Dravet and Lennox‐Gastaut syndromes are being planned. Trials in other treatment‐resistant epilepsies may also be warranted.A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.

1 March 2013 in Trends in Neurosciences
Verified
Journal Article
Closed access
ODOrrin Devinsky
Orrin Devinsky
AVAnnamaria Vezzani
Annamaria Vezzani
SNSouhel Najjar
Souhel Najjar
NLNihal C. De Lanerolle
Nihal C. De Lanerolle
MRMichael A. Rogawski
Michael A. Rogawski